Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Pseudogenes May Help in the Discovery of Biomarkers

July 7, 2014 11:06 am | News | Comments

Alas, the thankless pseudogene: dysfunctional, unloved and seemingly of little use, these poor-cousin relatives of genes have lost their protein-coding abilities, contain material not essential for an organism’s survival and are the “last stop” for removal of genomic waste. Read more...

TOPICS:

MRC Technology, AstraZeneca Renew Drug Target Collaboration

July 7, 2014 10:57 am | News | Comments

MRC Technology and AstraZeneca announced the renewal of their strategic collaboration which focuses on the identification and selection of novel drug targets with the potential to become potent and selective therapeutics for the treatment of serious disease in the areas of oncology, inflammation and diabetes. Read more...

TOPICS:

U.S. Officials Barred from Americans’ Trial in China

July 7, 2014 10:51 am | News | Comments

U.S. diplomats will be barred from the trial in China of an American investigator for GlaxoSmithKline and her British husband who are charged with improperly selling personal information, a spokesman for the U.S. Embassy in Beijing said Friday. Read more...

TOPICS:
Advertisement

BI Gets Priority Review for IPF Drug

July 3, 2014 12:00 pm | News | Comments

Boehringer Ingelheim announced that the New Drug Application for its investigational compound nintedanib has been accepted for filing by the FDA and granted Priority Review designation. Read more...                

TOPICS:

FDA Grants Orphan Designation to Galderma’s Skin Disease Drug

July 3, 2014 12:00 pm | News | Comments

Galderma announced that the U.S. Food and Drug Administration granted Orphan Drug Designation status for the company’s trifarotene molecule for the treatment of congenital ichthyosis. Read more...               

TOPICS:

Insys Cannabidiol Snags Orphan Designation for Rare Epilepsy

July 3, 2014 12:00 pm | News | Comments

Insys Therapeutics Inc. announced that the FDA has granted orphan drug designation to its pharmaceutical cannabidiol (CBD) for the treatment of Dravet syndrome, a rare pediatric-onset epilepsy. Read more...             

TOPICS:

Bioelectronics Could Lead to a New Class of Medicine

July 3, 2014 12:00 pm | News | Comments

Imagine having tiny electronics implanted somewhere in your body that can regulate nerve signals and make symptoms of various disorders go away. That’s the vision of the field of bioelectronic medicine— the emerging discipline that has made enough promising advances to draw a big investment by a pharmaceutical giant. Read more...

TOPICS:

Marrow Transplants Can Reverse Adult Sickle Cell

July 3, 2014 12:00 pm | by Lindsey Tanner, AP Medical Writer | News | Comments

Bone marrow transplants can reverse severe sickle cell disease in adults, a small study by government scientists found, echoing results seen with a similar technique used in children. Read more...               

TOPICS:
Advertisement

Odor-Free Evaporation on Your Lab Bench

July 2, 2014 3:55 pm | Product Releases | Comments

Genevac announced a proprietary “odor reduction” function for its EZ-2 evaporator which enables it to be sited on the open bench rather than taking up valuable fume hood space. Read more...

TOPICS:

Jazz to Acquire Rights to Defibrotide from Sigma-Tau

July 2, 2014 3:50 pm | News | Comments

Jazz Pharmaceuticals plc announced that the company has signed a definitive agreement with Sigma-Tau Pharmaceuticals Inc. under which a subsidiary of Jazz Pharmaceuticals plc will acquire from Sigma-Tau rights to defibrotide in the United States and all other countries in the Americas. Read more...

TOPICS:

Coming Soon: A Harder-to-Abuse Zohydro

July 2, 2014 3:43 pm | News | Comments

The drugmaker Zogenix said a harder-to-abuse version of its powerful painkiller Zohydro could be reviewed by regulators this fall and, if approved, might hit the market early next year, and they are also working to develop a tablet version that maintains the medicine's extended-release properties even when it is crushed or chewed. Read more...

TOPICS:

BI Submits MAAs in Europe for COPD Combo Drug

July 2, 2014 3:34 pm | News | Comments

Boehringer Ingelheim announced the submission of Marketing Authorization Applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol Respimat as a maintenance bronchodilator treatment for patients with chronic obstructive pulmonary disease. Read more...

TOPICS:

Actavis Acquires Furiex Pharmaceuticals

July 2, 2014 3:28 pm | News | Comments

Actavis announced that its subsidiary Forest Laboratories has successfully completed its acquisition of Furiex Pharmaceuticals in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval. Read more...

TOPICS:

Some 500 Genes Differ in Bipolar Patients’ Neurons

July 2, 2014 3:16 pm | by Cynthia Fox, Science Editor | Articles | Comments

Neurons of patients with bipolar disorder (BP) differ from the norm in a “striking” 500 or so genes, according to preliminary data generated using the Nobel-Prize-winning iPSC (induced pluripotent stem cell) approach, by Salk Institute neuroscientist Fred Gage. Read more...

TOPICS:

“Extensive” Errors Prompt Retraction of Stem Cell Claim

July 2, 2014 3:06 pm | by Malcolm Ritter, AP Science Writer | News | Comments

Scientists who reported that they'd found a startlingly simple way to make stem cells withdrew that claim Wednesday, admitting to "extensive" errors in the research that meant "we are unable to say without a doubt" that the method works. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading